New Market Report: Lebanon Pharmaceuticals & Healthcare Report Q3 2013
Although Lebanon's pharmaceutical market will remain largely valued by patented medicines consumption, we expect a swifter uptake in generic medicines over the 2012-2022 period. However, this generic drug uptake is jeopardised by the ongoing Syrian civil war. Syria's civil unrest will continue to hinder pharmaceutical trade relations between Lebanon's import-dependent medicines market and key drugmakers in Israel and Jordan, namely Teva Pharmaceuticals and Hikma Pharmaceuticals. Rising Lebanese political and economic instability, will also negatively impact consumption of locally produced and...
View full press release